Skip to main content
. 2024 Jul 3;13(1):2372875. doi: 10.1080/2162402X.2024.2372875

Table 3.

Antitumoral treatment outcomes following immune checkpoint inhibitor-induced cytokine release syndrome.

Antitumoral treatment outcome value (n = 22)*
CR 1 (4,5%)
PD 15 (68%)
SD 1 (4,5%)
PR 5 (23%)
Median duration of response on ICI 12 months

CR = Complete response, PR = Partial response, SD= Stable disease, PD = Progressive disease, ICI = immune checkpoint inhibitor.

*22 patients had evaluable radiological assessment following CRS.